On August 26, 2022 Indi Molecular reported that it has been granted U.S. Patent 11,414,460 entitled "KRAS-Specific Cyclic Peptides, Compositions, and Methods of Using and Making" along with Institute for Systems Biology (Press release, Indi Molecular, AUG 26, 2022, View Source [SID1234618706]). The patent claims cover compositions and methods for making and using cyclic peptide that selectively binds K-Ras G12D.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Given the frequency with which KRAS mutations are found in tumors, inhibition of this protein provides a potentially promising avenue for treatment of cancer," said Albert A. Luderer, Ph.D., chief executive and co-founder, Indi Molecular. "KRAS mutations are present in up to 30% of all tumors, including as many as 90% of pancreatic cancers."
Indi Molecular’s KRAS program builds on the synthetic platform developed by Indi Molecular and California Institute for Technology on protein catalyzed capture agents. James Heath, Ph.D., president and professor at Institute for Systems Biology, is the lead inventor of the KRAS and PCC technology. Heath is also a co-founder of Indi Molecular and serves as a board member and as a senior consultant for research and development.
"This composition of matter patent covers compounds, compositions, and methods involving cyclic peptides that can bind to KRAS (G12D) oncogenic protein. This is the third issued patent in the KRAS family of patents. The granted patent provides further evidence of the potential use of cyclic peptides in our oncology programs" said Sherri Candelario, Ph.D., vice president of intellectual property, Indi Molecular.